Tempus was recognized for its leadership in bridging the gap between data and technology to make genomic testing and clinical analysis more intelligent for patients. In naming Tempus to its list of the most influential companies, TIME highlighted the impact of xT CDx, Tempus' FDA-approved 648-gene tissue-based NGS test for molecular profiling of all malignant solid tumors. The recognition also noted Tempus' acquisition of Ambry Genetics, which integrated comprehensive germline and pediatric capabilities int ...